Brazil Potash Corp. (GRO)

Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-63.36	-46.41	-13.21	-32.62	-4.03	-11.23
Stock-Based Compensation	50.09	35.73	4.7	24.47	0.36	7.76
Other Operating Activities	-0.49	-0.22	-0.14	-0.1	0.49	0.33
Change in Accounts Receivable	-0.53	-0.45	0.02	0.89	-0.54	-0.18
Change in Accounts Payable	1.11	1.33	0.57	-0.86	-5.84	2.62
Change in Other Net Operating Assets	-1.73	-1.26	-0.14	0	-0.05	-0
Operating Cash Flow	-14.91	-11.28	-8.2	-8.22	-9.61	-0.71
Capital Expenditures	-4.22	-3.78	-3.94	-3.73	-1.17	-1.09
Other Investing Activities	0.19	0.02	0.3	0.26	0.01	0.02
Investing Cash Flow	-4.02	-3.77	-3.64	-3.47	-1.16	-1.07
Short-Term Debt Issued	-	-	-	-	-	0.63
Long-Term Debt Issued	-	-	-	-	0.81	-
Total Debt Issued	-	-	-	-	0.81	0.63
Long-Term Debt Repaid	-	-0.04	-	-	-3.23	-
Total Debt Repaid	-0.07	-0.04	-	-	-3.23	-
Net Debt Issued (Repaid)	-0.07	-0.04	-	-	-2.41	0.63
Issuance of Common Stock	31.69	31.65	2.5	8.35	28.29	-
Financing Cash Flow	31.62	31.61	2.5	8.35	25.88	0.63
Foreign Exchange Rate Adjustments	-0.1	-0.16	-0.02	0	-0.03	-0.13
Net Cash Flow	12.59	16.41	-9.35	-3.34	15.07	-1.29
Free Cash Flow	-19.13	-15.06	-12.13	-11.95	-10.78	-1.8
Free Cash Flow Per Share	-0.52	-0.42	-0.34	-0.34	-0.33	-0.06
Levered Free Cash Flow	4.76	2.38	-7.13	1.93	-11.46	2.36
Unlevered Free Cash Flow	4.76	2.38	-7.13	1.93	-11.21	2.48
Change in Net Working Capital	1.19	0.42	-0.46	-1.6	8.23	-2.56

Updated Nov 18, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q